JMDPC Law

Actos and Bladder Cancer : Traditionally, the surgery is performed through a lower abdominal incision in the midline from just below the umbilicus (i.e., “belly button”). Hospitalization for this procedure is generally between 5 and 10 days, and up to 6 weeks are needed for complete recovery. In recent years minimally invasive surgical approaches that replicate the technique of open radical cystectomy have been developed. Both laparoscopic and robotic-assisted radical cystectomies are currently being performed at highly specialized cen­ters. The principles of the surgery are the same, but the procedure is performed through smaller incisions using laparoscopic instruments. Using robotic assistance, your surgeon is able to perform complex operations with higher precision, under magnification. These approaches offer die potential advantage of a shorter recovery time, less blood loss, and less postoperative pain,

More information on Actos and Bladder Cancer

A pelvic lymph node dissection should be performed at the time of your surgery. This involves removal of the lymph node tissue in the most common areas of bladder cancer metastasis (spread of the cancer). The pelvic lymph node dissection has two important roles: to stage the cancer and to guide therapy. Individuals who are found to have cancer in the lymph nodes at the time of surgery generally require additional therapy such as chemotherapy. Studies have shown that up to 30 percent of patients with disease- positive lymph nodes who undergo a pelvic lymph node dissection will be free of disease at 5 years. Although there is debate among urologists as to exactiy how extensive ofapelvic lymph node dissection should be performed, there is no de­bate that one should be performed. Although a pelvic lymph node dissection can add an additional 30-90 minutes to your procedure time, there is little additional morbidity associ­ated when performed by an experienced surgeon.

Information from other sources on Actos and Bladder Cancer

Regardless of the approach, anyone who undergoes a radical cystectomy will require a form of urinary diversion because the bladder will no longer be there to store urine. This can have a significant psychological and functional impact on an individual’s quality of life. Patients are often hesitant to undergo definitive surgery because of the anxiety associated with long-term urinary diversion. There are two main types of urinary diversion: continent and noncontinent. Both forms require surgically removing a segment of bowel (most commonly the small bowel) from your gastrointestinal (GI) tract and plugging the ureter from each kidney into this segment of bowel to provide drainage of urine. Noncontinent diversions (ileal conduit) are those in which the piece of bowel is brought up through the abdominal wall to a stoma and the urine drains contin­uously into a drainage bag. This is die most common type of urinary diversion performed in the United States. This procedure requires approximately 8 to 10 centimeters (3 to 4 inches) of small bowel, which is far less than that used for continent urinary diversions. Although the obvious dis­advantage of this procedure is its lack of continence and need for a continuous drainage bag, it has less short- and long-term complications than that of the continent diver­sion. An external urinary drainage appliance is very well tolerated and patients adapt to them very quickly.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Actos and Bladder Cancer : This is what is usually called a “false-positive” test result. The test was positive in a case where it seems that it should have been negative. Any medical test has a cer­tain false-positive rate (usually very low). The problem with a false-positive result with urine cytology is that there is no way to guarantee the absence of cancer. It is always possible that the cancer is there, but we have not been able to find it yet. Sometimes it can hide in places such as the ureters or kidney where we cannot see as well. Other times, especially with carcinoma in situ, the diseased areas look normal through the cysto- scope but actually harbor serious disease. Because of this, one should never ignore a positive cytology result. Close to 80% of patients with a positive cytology but a negative evaluation will eventually be found to have a urologic malignancy.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

The current recommendation for patients with a posi­tive urine cytology and a negative initial evaluation is to repeat the urine cytology 6 to 8 weeks later. Those patients with a negative cytology on the follow-up test do not need further evaluation. If the follow-up cytol­ogy is positive, however, careful evaluation should be undertaken, as most of these patients will eventually be found to have a malignancy. Your urologist may rec­ommend multiple small biopsies of the bladder to look for carcinoma in situ, a condition that is often associ­ated with positive cytology.

Although cytology has long been the gold standard for bladder cancer screening, including monitoring for recur­rences, it is far from perfect (see Question 33), and there is great interest in finding an even better test. Currently, at least four other markers are approved by the Food and Drug Administration (FDA), although none of them are clearly better than cytology. In addition to these four, many new tests are being developed. The four listed here are those that are currently available to patients. If you are considering a radical cystec­tomy, you want an individual who regularly performs that operation. A radical cystectomy is a complicated, time-consuming procedure that some urologists rarely or never perform. The old dictum “practice makes perfect” certainly applies here. Furthermore, if you are interested in the neobladder option for reconstruction of your urinary tract, you should make sure that the urologist is comfortable with that portion of the oper­ation. The neobladder adds complexity to the proce­dure for the surgeon, and not all urologists are well trained in this area. The urologist should know his or her own complication rate for the procedure and not just quote widely published rates for other surgeons. He or she should be comfortable and willing to discuss these rates with you.

Information from other sources on Actos and Bladder Cancer

Cancer can be a frightening word and disease no matter how you look at it. You want a physician who understands your fears and concerns and who is willing to take the time to help you make your management decisions. There is no good measure for this, but trust your instincts at your first meeting with a new doctor. Sometimes you may feel that it is necessary to get a second opinion. You may have concerns about the treatment recommendations or may worry that there are other options that have not been presented. If you ever feel that you have not received enough informa­tion or that you are uncomfortable with the treatment recommendations from your urologist and/or oncolo­gist, then it is appropriate to seek a second opinion.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Actos and Bladder Cancer: Due to the ease of obtaining voided urine specimens, bladder cancer is on the forefront of developing tumor markers. Drs. McNeil, Ekwenna, and Getzenberg take an in depth look at various tumor markers and molecular signatures of bladder cancer in Chap. 6. Although several new tumor markers for bladder cancer are discovered each year and are the subject of numerous review articles, only few reviews are written on the subject of healthcare cost associated with bladder cancer diagnosis, screening, and surveillance. Chapter 7 by Yair Lotan is devoted to the subject of cost associated with bladder cancer detection and surveillance in the general versus high-risk population and using noninvasive techniques such as hematuria detection and tumor markers.

More information on Actos and Bladder Cancer

Prognostic markers and molecular nomograms involving proteomics and genom­ics are highly researched and some of the new emerging areas in bladder cancer. In Chap. 8, Dr. Habuchi focuses on seven different classes of molecules ranging from cell adhesion molecules to genetic alterations, which have been investigated for pre­dicting disease progression, response to treatment (local versus systemic control of the disease),

and survival. Chapter 9 by Smith and Theodorescu dwells on a novel idea of molecular nomograms for personalized medicine. While Chap. 8 includes information on individual markers, this chapter focuses on multiplexing of molecular biomarkers to predict response to therapy. Of note is COXEN or Co-expression Extrapolation) algorithm that compares microarray gene expression profiles between cell lines and patient tumors to generate signatures predictive of drug sensitivity or resistance.

Information from other sources on Actos and Bladder Cancer

Bladder cancer being a complex disease, a practical guide that provides the nec­essary facts at the fingertips is very useful and Chap. 10 by Drs. Levy and Jones provides just that for the management of nonmuscle invasive bladder cancer. Specifically the chapter provides a succinct description of epidemiology, etiology, pathophysiology, clinical and diagnostic evaluations, available molecular markers for disease, as well as the current American Urological Association Guidelines Panel Recommendations and therapies for nonmuscle invasive and recurrent blad­der cancer.Chapters 11-22 encompass clinical management of bladder cancer. Starting from the low-grade bladder cancer, Chap. 11 by Dr. William Oosterlink focuses on histology, risk factors, and diagnosis and detection of low-grade tumors in the blad­der and the upper tract, whereas Chap. 12 by Allaparthi and Balaji covers the clini­cal management of low-grade tumors.

Intravesical chemotherapy or immunotherapy (Bacillus Calmette-Guerin [BCG]) are key adjuvant therapies for the control of high-grade nonmuscle invasive bladder cancer. In Chap. 13, Drs. Adiyat, Katkoori, and Soloway is a review of indications and practical aspects of administration of intravesical chemotherapy, properties, efficacy, and side effects of various intravesical agents, and newer methods improv­ing the efficacy of the intravesical drugs. Although, many reviews have been writ­ten on intravesical BCG therapy, the review by Drs. Bishay, Park, and Hemstreet is unique because of the depth of discussion on the mechanism of action of BCG in animal versus cell culture models, and the involvement of the immune system and inflammatory cytokines/chemokines in mediating response to BCG.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : Your physicians should be confident enough in their recommendations that they are neither intimidated nor angered by your desire to seek a second opinion. If you experience either of these reactions, then you can be confident in your decision to seek a second opinion. Generally, your physicians will hope that you return to them to discuss the second opinion afterward, espe­cially regarding anything that is divergent from their own recommendations. Most patients return to their original caregiver after getting a second opinion, although you are never obligated to do so.

Most patients will not need to stay in the hospital overnight after a TURBT. The final decision on stay­ing in the hospital or returning home is made based on the amount of resection necessary and the amount of blood in the urine after the procedure. These two fac­tors will also determine whether a catheter needs to be left in place after the procedure, usually for a few days. TURBT is generally regarded as a low-risk procedure. It is typically performed as a day surgery procedure, meaning that you will not need to stay in the hospital overnight. As with any surgery that requires anesthe­sia, a small risk is associated with the anesthesia. This risk is higher if you have other conditions such as asthma, chronic obstructive pulmonary disease, or car­diovascular disease, but is still generally very low risk.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Perioperative chemotherapy refers to the practice of instilling one of the bladder chemotherapies immedi­ately after TURBT, usually while you are still in the operating room or the recovery room. Traditionally, these intravesical therapies have been given after the bladder has healed, 2 to 3 weeks after surgery. Several studies in the last 10 years have shown benefits to giv­ing a single dose of chemotherapy at the time of TURBT. The benefit presumably derives from killing any cancer cells that are still swirling around in the bladder after TURBT, thus preventing them from implanting in the bladder.

Information from other sources on Actos and Bladder Cancer

PDT is a new treatment that is still evolving. It is cur­rently given only to patients with recurrent tumors who have failed BCG treatment. Newer sensitizing agents have improved its efficacy. In one study, 84% of patients with BCG-resistant papillary tumor had a complete response, and 75% of patients with carci­noma in situ had a complete response at the 3-month follow-up. At a median follow-up of 4 years, 31 of 34 patients who had responded were still tumor-free. PDT appears to be useful in patients with superficial bladder cancer but has not yet been widely adopted.

Superficial bladder cancer is a recurrent and potentially progressive disease. Most studies have shown that patients with a higher stage and/or grade (Questions 29 and 30) have recurrences more frequently than do patients with a lower stage or grade. Approximately half of the lowest stage and grade tumors (Ta, Grade I/II) will recur, most of them in the first 3 months after treat­ment. Carcinoma in situ recurs in up to 70% of patients.

The treatment of choice currently for carcinoma in situ is intravesical therapy with BCG (Question 35). Carci­noma in situ in most cases is not adequately treated by resection alone because it tends to be located diffusely throughout the bladder. Sixty to 70% of patients with carcinoma in situ will respond to a standard course of BCG. Although encouraging, this obviously means that 30% to 40% of patients will fail a standard course, and thus most experts advise further therapy. Some advocate two courses of BCG, whereas others prefer maintenance BCG for 3 years; urine is sent for cytology every 3 to 12 months. Also, periodic cystoscopy will need to be performed in the urologist’s office, and any suspicious lesions will need to be biopsied and exam­ined under the microscope by a pathologist.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : CAN ALL BLADDER TUMORS BE REACHED WITH A RESECTOSCOPE?

On occasion, a urologist may face an individual with a bladder tumor that cannot be reached. This is usually much more of an issue with male patients since the scope is required to pass through a much longer urethra to begin with, therefore reducing the amount of instrument available to work within the bladder. Contributing factors include:

Tumor location: tumors loeated at the dome (the very top part of the bladder or those just inside the bladder neck) may be extremely difficult to remove.

Body size: individuals who are markedly obese have distorted internal anatomy. Instruments may not be long enough to reach all bladder tumors.

Enlarged bladders: individuals with abnormally large bladders may have tumors beyond the reach of the resectoscope.

More information on Actos and Bladder Cancer

Bladder diverticulum: some bladders have an abnormal cavity called a diverticulum. If the opening to the diverticulum is small or if the diverticulum is large, bladder tumor removal may be difficult. In addition, the walls of the diverticulum are quite thin, making tumor removal more hazardous, as perforation is more likely to occur.

Information from other sources on Actos and Bladder Cancer

WHAT CAN MY UROLOGIST DO TO ENHANCE HIS ABILITY TO REMOVE TUMORS IN DIFFICULT LOCATIONS?

The experienced urologist uses several techniques to improve his chances of removing tumors that are difficult to reach. He will often keep the bladder under filled. Although this may reduce visibility, it will allow the tumor to be closer to the resectoscope. Another technique is to place manual pressure on the bladder from above. This is done by an assistant or by the urologist himself. By pushing down from above, tumors at the dome are displaced downwards. An additional technique, for the male patient, is operating through a perineal urethrostomy. The urologist makes a surgical opening into the urethra between the scrotum and rectum, allowing the resectoscope to move further into the bladder, bypassing much of the urethra.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer 12/20/2011: As new drugs are introduced and new combinations of drugs are tested, statistics regarding effectiveness are constantly changing. Side effects too can vary, depending on the individual. However, most patients will experience the side effects to various degrees, and these need to be fully understood prior to proceeding.

In the end, it is the individual’s decision as to whether to begin or end chemotherapy. For many, trying chemo and seeing the effect on the cancer is a sound decision. If the cancer does not respond or if the patient finds the side effects unacceptable, chemotherapy can be stopped. It is extremely important for you to have an oncologist who will work with you closely. Your oncologist should understand your feelings regarding cancer treatment fully.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Lawyer , Actos Lawsuit is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the

maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection

with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Attorney12/15/2011: The elderly, frail individuals with multiple coexisting chronic illnesses, individuals that are weakened through mahiutrition or who have compromised immunity all would face substantially increased risk of complications from standard chemotherapy regimens for bladder cancer. Unfortunately, cisplatin is toxic to kidneys, and many individuals with bladder cancer have compromised kidney function which effectively rules out the use of platinum based chemotherapy. Other treatment regimens exist and are being worked on for these individuals, but none show the efficacy of the standard therapy which includes cisplatin.

For more information on Actos Attorney follow us on our RSS Feeds.

Our use of the Terms Actos Settlements, Actos and Bladder Cancer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com